Do analysts recommend VRAX or BIOL?

Virax Biolabs Group presently has a consensus target price of $25.00, indicating a potential upside of 786.52%. Given Virax Biolabs Group's stronger consensus rating and higher possible upside, research analysts plainly believe Virax Biolabs Group is more favorable than BIOLASE. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virax Biolabs Group 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 BIOLASE 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation & earnings, VRAX or BIOL?

Virax Biolabs Group has higher earnings, but lower revenue than BIOLASE. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virax Biolabs Group $12.42K 180.92 -$5.02M N/A N/A BIOLASE $48.83M 0.00 -$20.63M -$14.94 N/A

Do analysts rate BIOL or TNON?

Given BIOLASE's higher possible upside, equities analysts clearly believe BIOLASE is more favorable than Tenon Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BIOLASE 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Tenon Medical 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is BIOL or TNON more profitable?

BIOLASE has a net margin of -41.65% compared to Tenon Medical's net margin of -257.85%. Tenon Medical's return on equity of -907.60% beat BIOLASE's return on equity. Company Net Margins Return on Equity Return on Assets BIOLASE -41.65% -1,782.73% -55.31% Tenon Medical -257.85% -907.60% -124.84%

Do analysts rate BIOL or AEMD?

Aethlon Medical has a consensus price target of $1.50, indicating a potential downside of 39.76%. Given BIOLASE's higher probable upside, analysts clearly believe BIOLASE is more favorable than Aethlon Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BIOLASE 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Aethlon Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is BIOL or AEMD more profitable?

Aethlon Medical has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. Aethlon Medical's return on equity of -123.08% beat BIOLASE's return on equity. Company Net Margins Return on Equity Return on Assets BIOLASE -41.65% -1,782.73% -55.31% Aethlon Medical N/A -123.08% -99.28%

Do analysts rate BBLG or BIOL?

Given BIOLASE's higher probable upside, analysts clearly believe BIOLASE is more favorable than Bone Biologics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bone Biologics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BIOLASE 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is BBLG or BIOL more profitable?

Bone Biologics has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. Bone Biologics' return on equity of -57.87% beat BIOLASE's return on equity. Company Net Margins Return on Equity Return on Assets Bone Biologics N/A -57.87% -53.65% BIOLASE -41.65% -1,782.73% -55.31%

Which has higher earnings and valuation, BIOL or DYNT?

Dynatronics has lower revenue, but higher earnings than BIOLASE. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BIOLASE $48.83M 0.00 -$20.63M -$14.94 N/A Dynatronics $33.60M 0.00 -$2.70M -$1.35 N/A

Is BIOL or DYNT more profitable?

Dynatronics has a net margin of -8.35% compared to BIOLASE's net margin of -41.65%. Dynatronics' return on equity of -41.81% beat BIOLASE's return on equity. Company Net Margins Return on Equity Return on Assets BIOLASE -41.65% -1,782.73% -55.31% Dynatronics -8.35% -41.81% -9.56%

BIOLASE (BIOL) Competitors

Compare

BIOL vs. VRAX, TNON, AEMD, BBLG, and DYNT

Should you buy BIOLASE stock or one of its competitors? BIOLASE's main competitors and comparable companies include Virax Biolabs Group (VRAX), Tenon Medical (TNON), Aethlon Medical (AEMD), Bone Biologics (BBLG), and Dynatronics (DYNT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does BIOLASE compare to Virax Biolabs Group?

Virax Biolabs Group (NASDAQ:VRAX) and BIOLASE (NASDAQ:BIOL) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation.

8.6% of Virax Biolabs Group shares are held by institutional investors. Comparatively, 8.8% of BIOLASE shares are held by institutional investors. 45.1% of Virax Biolabs Group shares are held by insiders. Comparatively, 0.3% of BIOLASE shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Virax Biolabs Group presently has a consensus target price of $25.00, indicating a potential upside of 786.52%. Given Virax Biolabs Group's stronger consensus rating and higher possible upside, research analysts plainly believe Virax Biolabs Group is more favorable than BIOLASE.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BIOLASE	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Virax Biolabs Group has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. Virax Biolabs Group's return on equity of 0.00% beat BIOLASE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virax Biolabs Group	N/A	N/A	N/A
BIOLASE	-41.65%	-1,782.73%	-55.31%

Virax Biolabs Group has higher earnings, but lower revenue than BIOLASE.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virax Biolabs Group	$12.42K	180.92	-$5.02M	N/A	N/A
BIOLASE	$48.83M	0.00	-$20.63M	-$14.94	N/A

In the previous week, Virax Biolabs Group had 2 more articles in the media than BIOLASE. MarketBeat recorded 2 mentions for Virax Biolabs Group and 0 mentions for BIOLASE. Virax Biolabs Group's average media sentiment score of 0.62 beat BIOLASE's score of 0.00 indicating that Virax Biolabs Group is being referred to more favorably in the media.

Company	Overall Sentiment
Virax Biolabs Group	Positive
BIOLASE	Neutral

Virax Biolabs Group has a beta of 1.35, indicating that its share price is 35% more volatile than the broader market. Comparatively, BIOLASE has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market.

Summary

Virax Biolabs Group beats BIOLASE on 11 of the 13 factors compared between the two stocks.

How does BIOLASE compare to Tenon Medical?

BIOLASE (NASDAQ:BIOL) and Tenon Medical (NASDAQ:TNON) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

In the previous week, Tenon Medical had 7 more articles in the media than BIOLASE. MarketBeat recorded 7 mentions for Tenon Medical and 0 mentions for BIOLASE. Tenon Medical's average media sentiment score of 0.32 beat BIOLASE's score of 0.00 indicating that Tenon Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
BIOLASE	Neutral
Tenon Medical	Neutral

8.8% of BIOLASE shares are held by institutional investors. Comparatively, 22.7% of Tenon Medical shares are held by institutional investors. 0.3% of BIOLASE shares are held by insiders. Comparatively, 17.7% of Tenon Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Given BIOLASE's higher possible upside, equities analysts clearly believe BIOLASE is more favorable than Tenon Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BIOLASE	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Tenon Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Tenon Medical has lower revenue, but higher earnings than BIOLASE. Tenon Medical is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BIOLASE	$48.83M	0.00	-$20.63M	-$14.94	N/A
Tenon Medical	$5.31M	0.32	-$12.56M	-$44.87	N/A

BIOLASE has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market. Comparatively, Tenon Medical has a beta of 1.39, meaning that its share price is 39% more volatile than the broader market.

BIOLASE has a net margin of -41.65% compared to Tenon Medical's net margin of -257.85%. Tenon Medical's return on equity of -907.60% beat BIOLASE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BIOLASE	-41.65%	-1,782.73%	-55.31%
Tenon Medical	-257.85%	-907.60%	-124.84%

Summary

Tenon Medical beats BIOLASE on 9 of the 15 factors compared between the two stocks.

How does BIOLASE compare to Aethlon Medical?

BIOLASE (NASDAQ:BIOL) and Aethlon Medical (NASDAQ:AEMD) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

Aethlon Medical has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. Aethlon Medical's return on equity of -123.08% beat BIOLASE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BIOLASE	-41.65%	-1,782.73%	-55.31%
Aethlon Medical	N/A	-123.08%	-99.28%

8.8% of BIOLASE shares are owned by institutional investors. Comparatively, 2.0% of Aethlon Medical shares are owned by institutional investors. 0.3% of BIOLASE shares are owned by company insiders. Comparatively, 0.7% of Aethlon Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Aethlon Medical has a consensus price target of $1.50, indicating a potential downside of 39.76%. Given BIOLASE's higher probable upside, analysts clearly believe BIOLASE is more favorable than Aethlon Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BIOLASE	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aethlon Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Aethlon Medical had 4 more articles in the media than BIOLASE. MarketBeat recorded 4 mentions for Aethlon Medical and 0 mentions for BIOLASE. Aethlon Medical's average media sentiment score of 0.58 beat BIOLASE's score of 0.00 indicating that Aethlon Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
BIOLASE	Neutral
Aethlon Medical	Positive

Aethlon Medical has lower revenue, but higher earnings than BIOLASE. Aethlon Medical is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BIOLASE	$48.83M	0.00	-$20.63M	-$14.94	N/A
Aethlon Medical	N/A	N/A	-$7.15M	-$34.97	N/A

BIOLASE has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market. Comparatively, Aethlon Medical has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market.

Summary

Aethlon Medical beats BIOLASE on 8 of the 14 factors compared between the two stocks.

How does BIOLASE compare to Bone Biologics?

Bone Biologics (NASDAQ:BBLG) and BIOLASE (NASDAQ:BIOL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

Bone Biologics has higher earnings, but lower revenue than BIOLASE. Bone Biologics is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bone Biologics	N/A	N/A	-$3.11M	-$1.37	N/A
BIOLASE	$48.83M	0.00	-$20.63M	-$14.94	N/A

In the previous week, Bone Biologics had 3 more articles in the media than BIOLASE. MarketBeat recorded 3 mentions for Bone Biologics and 0 mentions for BIOLASE. Bone Biologics' average media sentiment score of 0.57 beat BIOLASE's score of 0.00 indicating that Bone Biologics is being referred to more favorably in the media.

Company	Overall Sentiment
Bone Biologics	Positive
BIOLASE	Neutral

34.3% of Bone Biologics shares are held by institutional investors. Comparatively, 8.8% of BIOLASE shares are held by institutional investors. 5.6% of Bone Biologics shares are held by company insiders. Comparatively, 0.3% of BIOLASE shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Given BIOLASE's higher probable upside, analysts clearly believe BIOLASE is more favorable than Bone Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BIOLASE	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Bone Biologics has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market. Comparatively, BIOLASE has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market.

Bone Biologics has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. Bone Biologics' return on equity of -57.87% beat BIOLASE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bone Biologics	N/A	-57.87%	-53.65%
BIOLASE	-41.65%	-1,782.73%	-55.31%

Summary

Bone Biologics beats BIOLASE on 11 of the 14 factors compared between the two stocks.

How does BIOLASE compare to Dynatronics?

BIOLASE (NASDAQ:BIOL) and Dynatronics (NASDAQ:DYNT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

BIOLASE has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market. Comparatively, Dynatronics has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market.

Dynatronics has a net margin of -8.35% compared to BIOLASE's net margin of -41.65%. Dynatronics' return on equity of -41.81% beat BIOLASE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BIOLASE	-41.65%	-1,782.73%	-55.31%
Dynatronics	-8.35%	-41.81%	-9.56%

Dynatronics has lower revenue, but higher earnings than BIOLASE.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BIOLASE	$48.83M	0.00	-$20.63M	-$14.94	N/A
Dynatronics	$33.60M	0.00	-$2.70M	-$1.35	N/A

In the previous week, BIOLASE's average media sentiment score of 0.00 equaled Dynatronics'average media sentiment score.

Company	Overall Sentiment
BIOLASE	Neutral
Dynatronics	Neutral

8.8% of BIOLASE shares are held by institutional investors. Comparatively, 4.2% of Dynatronics shares are held by institutional investors. 0.3% of BIOLASE shares are held by company insiders. Comparatively, 2.9% of Dynatronics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Dynatronics beats BIOLASE on 6 of the 10 factors compared between the two stocks.

Get BIOLASE News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIOL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BIOL vs. The Competition

Export

Metric	BIOLASE	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$581K	$5.78B	$7.18B	$12.89B
Dividend Yield	N/A	1.75%	2.54%	11.27%
P/E Ratio	0.00	25.92	273.17	25.45
Price / Sales	N/A	78.92	638.21	103.75
Price / Cash	N/A	33.69	28.74	36.03
Price / Book	N/A	6.18	11.08	6.36
Net Income	-$20.63M	$149.94M	$3.48B	$349.79M

BIOLASE Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BIOL BIOLASE	N/A	N/A	N/A	N/A	$581K	$48.83M	N/A	160
VRAX Virax Biolabs Group	2.4652 of 5 stars	$2.77 -4.8%	$25.00 +802.5%	-81.4%	$2.32M	$10K	N/A	5	Gap Up
TNON Tenon Medical	1.4414 of 5 stars	$5.21 -7.3%	N/A	-88.5%	$1.90M	$3.94M	N/A	8	Analyst Upgrade Gap Up
AEMD Aethlon Medical	1.4493 of 5 stars	$2.28 -5.0%	$1.50 -34.2%	-97.3%	$1.71M	N/A	N/A	10	Gap Up
BBLG Bone Biologics	0.723 of 5 stars	$0.62 +1.9%	N/A	-71.4%	$1.67M	N/A	N/A	2	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BIOL) was last updated on 8/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BIOLASE (BIOL) Competitors

BIOL vs. VRAX, TNON, AEMD, BBLG, and DYNT

How does BIOLASE compare to Virax Biolabs Group?

Summary

How does BIOLASE compare to Tenon Medical?

Summary

How does BIOLASE compare to Aethlon Medical?

Summary

How does BIOLASE compare to Bone Biologics?

Summary

How does BIOLASE compare to Dynatronics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIOL vs. The Competition

BIOLASE Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BIOLASE (BIOL) Competitors

BIOL vs. VRAX, TNON, AEMD, BBLG, and DYNT

How does BIOLASE compare to Virax Biolabs Group?

Do insiders and institutionals believe in VRAX or BIOL?

Do analysts recommend VRAX or BIOL?

Is VRAX or BIOL more profitable?

Which has stronger valuation & earnings, VRAX or BIOL?

Does the media refer more to VRAX or BIOL?

Which has more risk and volatility, VRAX or BIOL?

Summary

How does BIOLASE compare to Tenon Medical?

Does the media prefer BIOL or TNON?

Do insiders & institutionals hold more shares of BIOL or TNON?

Do analysts rate BIOL or TNON?

Which has preferable earnings & valuation, BIOL or TNON?

Which has more risk and volatility, BIOL or TNON?

Is BIOL or TNON more profitable?

Summary

How does BIOLASE compare to Aethlon Medical?

Is BIOL or AEMD more profitable?

Do institutionals and insiders have more ownership in BIOL or AEMD?

Do analysts rate BIOL or AEMD?

Does the media favor BIOL or AEMD?

Which has stronger earnings and valuation, BIOL or AEMD?

Which has more volatility and risk, BIOL or AEMD?

Summary

How does BIOLASE compare to Bone Biologics?

Which has higher earnings and valuation, BBLG or BIOL?

Does the media favor BBLG or BIOL?

Do institutionals & insiders believe in BBLG or BIOL?

Do analysts rate BBLG or BIOL?

Which has more volatility & risk, BBLG or BIOL?

Is BBLG or BIOL more profitable?

Summary

How does BIOLASE compare to Dynatronics?

Which has more volatility & risk, BIOL or DYNT?

Is BIOL or DYNT more profitable?

Which has higher earnings and valuation, BIOL or DYNT?

Does the media favor BIOL or DYNT?

Do insiders and institutionals have more ownership in BIOL or DYNT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIOL vs. The Competition

BIOLASE Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools